AstraZeneca, Lilly Partner for Alzheimer’s Disease DrugBy
AstraZeneca and Eli Lilly and Company have entered a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42) in Phase I trials as a potential treatment for Alzheimer’s disease (AD).
This agreement builds on the existing collaboration between the two companies for the co-development of AZD3293, an oral beta secretase cleaving enzym (BACE) inhibitor in two Phase III trials for AD.
Under the new agreement, Lilly will make a $30 million upfront payment to AstraZeneca. Lilly will recognize the upfront of $30 million (pretax) as a charge to earnings in the fourth quarter of 2016.